Serum containing Buyang Huanwu decoction prevents age-associated migration and invasion of human vascular smooth muscle cells by up regulating SIRT1 expression

Zhang, Li; Wei, Chunshan; Ruan, Yunjun; Zhang, Yanan; Zhou, Yuliang; Lei, Da

doi:10.5582/bst.2018.01063

Cited by 7 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum containing BYHWD (BYHWS) attenuated Ang IIinduced VSMC senescence. Furthermore, SIRT1 knockdown through siRNA abolished the protective role of BYHWS in VSMCs (Zhang et al, 2018).…”

Section: Introductionmentioning

confidence: 93%

Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases

Wang

Chen

2020

Front. Pharmacol.

View full text Add to dashboard Cite

Vascular smooth muscle cells (VSMCs), located in the media of artery, play key roles in maintaining the normal vascular physiological functions. Abnormality in VSMCs is implicated in vascular diseases (VDs), including atherosclerosis, abdominal aortic aneurysm (AAA), aortic dissection, and hypertension by regulating the process of inflammation, phenotypic switching, and extracellular matrix degradation. Sirtuins (SIRTs), a family of proteins containing seven members (from SIRT1 to SIRT7) in mammals, function as NAD +-dependent histone deacetylases and ADPribosyltransferases. In recent decades, great attention has been paid to the cardiovascular protective effects of SIRTs, especially SIRT1, suggesting a new therapeutic target for the treatment of VDs. In this review, we introduce the basic functions of SIRT1 against VSMC senescence, and summarize the contribution of SIRT1 derived from VSMCs in VDs. Finally, the potential new strategies based on SIRT1 activation have also been discussed with an emphasis on SIRT1 activators and calorie restriction to improve the prognosis of VDs.

show abstract

“…Serum containing BYHWD (BYHWS) attenuated Ang IIinduced VSMC senescence. Furthermore, SIRT1 knockdown through siRNA abolished the protective role of BYHWS in VSMCs (Zhang et al, 2018).…”

Section: Introductionmentioning

confidence: 93%

Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases

Wang

Chen

2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Astragalus membranaceus is a traditional Chinese medicinal material. It has been widely used in clinics for the treatment of cardiovascular, cerebrovascular diseases, liver disease, kidney disease, tumours and aging [1,38,44,64,65]. It has a distinct role with specified formulations or in combination with other drugs.…”

Section: Introductionmentioning

confidence: 99%

Astragaloside IV inhibits experimental autoimmune encephalomyelitis by modulating the polarization of both microglia/macrophages and astrocytes

Yu,

Mu,

Guo

et al. 2023

View full text Add to dashboard Cite

Astragaloside IV (AST IV), a major saponin component and active ingredient isolated from Astragalus membranaceus, has been well known to exhibit neuroprotective effects on diverse models of neurological diseases. Accumulating evidence suggests that dynamic balance of microglia/macrophages and astrocytes plays a vital role in neuroprotection and remyelination. However, dysregulation of microglia/macrophages and astrocytes orchestrate the pathogenesis of nervous system disorders. Therefore, we hypothesized that switching the transformation of microglia/macrophages and astrocytes into the neuroprotective M2 and A2 phenotypes, respectively, could be a potential target for therapeutic intervention.In the present study, we evaluate the efficacy of AST IV intervention on the effects of microglia/macrophages and astrocytes in an experimental autoimmune encephalomyelitis (EAE) model. AST IV improved paralysis and pathology of EAE by inhibiting the neurotoxic M1 microglia/macrophage phenotype, promoting M2 phenotype, shifting astrocytes towards a neuroprotective A2 phenotype, and protecting neurons from apoptosis through inhibition of TLR4/Myd88/NF-κB signalling pathway. Our study showed that AST IV could be a potential and promising drug for multiple sclerosis treatment.

show abstract